BML, Inc. (MUN:BMZ)

Germany · Delayed Price · Currency is EUR

23.60

+0.80 (3.51%)

At close: Feb 27, 2026

35.63% (1Y)

Market Cap	885.21M
Revenue (ttm)	809.87M
Net Income (ttm)	41.07M
Shares Out	n/a
EPS (ttm)	1.07
PE Ratio	21.56
Forward PE	n/a
Dividend	0.77 (3.28%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	n/a
Open	23.60
Previous Close	22.80
Day's Range	23.60 - 23.60
52-Week Range	16.40 - 23.60
Beta	n/a
RSI	72.97
Earnings Date	Feb 6, 2026

About BML, Inc.

BML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispe... [Read more]

Industry Commercial Physical and Biological Research

Founded 1955

Employees 4,558

Stock Exchange Munich Stock Exchange

Ticker Symbol BMZ

Full Company Profile

Financial Performance

In fiscal year 2025, BML, Inc.'s revenue was 143.19 billion, an increase of 3.79% compared to the previous year's 137.96 billion. Earnings were 6.26 billion, an increase of 3.80%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.